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Microstructural-Mechanical interactions of Drug Coated Balloons 
Christopher Wu, John Warrington, Jesse Lauber, Justin Gerow 
 
Abstract 
Peripheral Artery Disease (PAD) is a common subset of atherosclerosis characterized by            
plaque build-up in the arteries of the lower extremities. Current therapies include drug eluting              
stents (DESs) and drug coated balloons (DCBs). DCBs offer a more promising therapy than              
DESs because they do not require a permanent implant, they cost less, and prevent restenosis of                
the artery longer. DCBs are made up of angioplasty balloons coated in an antiproliferative drug,               
usually paclitaxel, and are inserted into the artery via a guide wire. The balloon inflates at the                 
target site, mechanically compressing the plaque and delivering antiproliferative drug into the            
arterial wall which can prevent restenosis up to 14.5 months after treatment. Previous studies              
within our lab show that the excipient microstructure of the DCB can modulate the amount of                
drug transferred into the arterial wall. Therefore, we set out to determine what factors control the                
formation and morphology of excipient microcrystals and how these properties correlate to drug             
delivery. We hypothesized that the dehydration temperature of urea (excipient) and paclitaxel            
(drug) solution on Nylon-12 sheets at temperatures of 4℃, 23℃, and 37℃ will affect the rate                
and size of crystal formation thereby altering drug transfer. We also hypothesized that the              
substrate hydrophobicity will impact drug delivery. To alter substrate hydrophobicity, we           
pre-treated the Nylon-12 sheet with UV/Ozone for 20m and 40m before coating application and              
dehydration at 23℃. Following SEM imaging of our samples, the coated nylon-12 sheets were              
mechanically compressed against a porcine artery at 8N and 12N for 30s and 180s using a                
uniaxial mechanical compression device. PTX was extracted from the arterial tissue and eluted             
through HPLC to determine drug transfer. There was no significant difference between drug             
transfer of the different dehydration temperatures with mean transfer rates of 5.11%, 4.7%, and              
4.39% for 4℃, 23℃, and 37℃ respectively (Kruskal-Wallis p = 0.12). There was a significant               
increase in drug transfer between no UV/Ozone pre-treatment (5.02%) and 20 minutes (28.28%)             
(p= 0.00092), no pre-treatment and 40m pre-treatment (12.99%) (p =0.0033), and between the             
20m pre-treatment and 40m pre-treatment (p = 0.031). In conclusion, temperature of dehydration             
plays no role in drug delivery, however, pre-treatment of Nylon-12 surface using UV/Ozone can              
dramatically increase drug delivery. Future studies will focus on optimizing the UV/Ozone            
pre-treatment for delivery of PTX into the arterial wall, quantifying microcrystal structures in             
SEM images using image processing software, and performing uniaxial mechanical testing to            
determine adhesion forces between the artery and the surface coating. 
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 [Problem Definition] 
Peripheral artery disease (PAD) is most commonly caused by atherosclerosis and is            
associated with the narrowing or blockage of arteries supplying blood to the extremities due to               
plaque buildup. PAD affects 10% - 25% of people above the age of 55 and in severe cases can                   
lead to limb loss, myocardial infarction, or stroke.​1,2 The need for treatment and management of               
PAD has led to the development of several endovascular interventions including drug eluting             
stents (DES) and angioplasty balloons. Even with rapid advancements in care, there are still              
major problems facing PAD endovascular intervention such as neointimal hyperplasia, stent           
fracture, and restenosis.​3 
 
Stents are impractical for PAD and other vascular blockages of the lower limbs as they               
have significantly increased rate of restenosis and the possibility of compressive mechanical            
failure. This failure, defined as the plastic deformation of the DES, renders it incapable of               
maintaining an open artery. Failure occurs when movement in the legs results in flexed muscles               
placing compressive forces on the DES. These drawbacks pave the way for Drug Coated              
Balloons (DCBs) to become the leading tool in a surgeon’s arsenal.​4,5 Drug coated balloons are               
thin, inflatable balloons made of Nylon-12 polymer that are coated with a mixture of excipient,               
typically urea, and a drug meant for delivery into the artery. DCBs allow for the rapid delivery of                  
an antiproliferative drug upon inflation of a drug coated angioplasty balloon. This is done              
through the use of a guide wire within the artery without the need for a permanent metal or                  
polymer implant as with a stent.​4 ​Figure 1 shows how a DCB is used in a balloon angioplasty                  
operation where the antiproliferative drug is delivered to the vessel wall. 
 
Figure 1. Drug Coated Balloon Angioplasty Process.​6 ​In part A, the balloon is placed in the                
affected area by use of a catheter wire. Part B shows the balloon being inflated to the size of the                    
lumen. Part C is a demonstration of the process where the excipient and antiproliferative drug are                
delivered to the vessel wall from the balloon surface. Part D is an ideal outcome where all of the                   
drug is delivered to the vessel wall so that there is no washout once the balloon is deflated and                   
blood flow returns. 
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DCBs have several advantages over DES including enhanced vessel healing and the            
potential for higher drug tissue bioavailability as a result of increased drug-coated surface area              
presented to the arterial wall. On top of these advantages, the average cost associated with               
treatment using DCBs is $10,214 whereas the average cost of using a DES is $12,904​7​. These                
advantages make DCBs a very favorable option. However, a significant drawback of DCBs is              
that they fail to provide mechanical support for the artery after removal and surgeons cannot use                
them to treat dissection flaps.​8  
 
Once inflated at the target site, DCBs release their payloads and are deflated after              
30-60 s.​4 Paclitaxel (PTX) is the most commonly used agent in DCBs by virtue of its               
antiproliferative effect on smooth muscle cells (SMCs). PTX works by permanently stabilizing            
microtubules thereby impeding mitotic cell division.​9 Through this mechanism, PTX has been            
shown to prevent restenosis up to 14.5 months after treatment.​10 One issue currently facing the               
adoption of DCBs involves the passage of drug into the arterial wall as well as the inherent drug                  
loss caused by the natural flow conditions of the arteries.​4,11 
  
Currently, DCBs exhibit a low efficiency of PTX delivery with nearly 90% of drug lost               
after inflation.​12 Increasing the vascular permeability for more efficient delivery of PTX is             
paramount and the excipient microstructure of crystalline carriers, such as urea, can have a large               
impact on the amount of drug that reaches the targeted SMCs. By increasing the size of the                 
excipient urea crystals, this will allow for increased bioavailability of PTX at the site of interest                
and reduced washout.​13 Larger crystals may also significantly impact the glycocalyx layer,            
affecting its ability recover post-inflation of the DCB.​14 
  
In the United States, two DCBs, the IN.PACT from Medtronic and Lutonix 035 DCB              
PTA Catheter from BARD, have received FDA approval and are being used clinically to treat               
PAD. These two products have shown long term safety and similar efficacy in clinical trials, yet                
the Lutonix is loaded with one third the concentration of PTX.​15,16 Previous work in our lab has                 
shown specific coating characteristics such as coating thickness, application technique, surface           
treatment, and excipient to PTX ratio play a major role in drug delivery. Coating technique has                
the capacity to alter the microstructure of the excipient and can ultimately affect the efficacy of                
the DCB treatment.​12 
  
[Problem Solution] 
Our research team believes that dehydration temperature and pre-treatment of the           
angioplasty balloon will significantly impact the ability to deliver PTX. We aim to generate              
unique coating structures which we will characterize with SEM imaging. This characterization            
will inform the results of our uniaxial testing and will help to develop relationships between               
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 coating technique and efficacious PTX delivery. We hypothesize that larger and more uniformly             
dispersed urea microcrystals will improve the delivery of PTX through DCBs. 
The factors we are exploring in our study of the excipient microstructure include the              
depth of surface coating, the technique for applying drug coating, the nylon surface             
pre-treatment, and the ratio of chemotherapeutic drug to excipient carrier. The depth of surface              
coating may be related to the available surface area for initial drug transfer and provides a means                 
for quantification. As the bulk of PTX is theorized to be deposited on the surface of the                 
crystalline urea microstructures, the average surface depth will be a factor for drug delivery. The               
surface depth is also proportional to the overall size of the urea microstructures; increase in urea                
microstructures will improve adhesion of the coating to the arterial endothelium, which            
lengthens the exposure allowed for PTX to diffuse into the endothelium.  
The techniques available to us for depositing the drug and excipient coating will not              
match those available to industry leaders in the DCB field. For this reason we will use drip                 
coating techniques similar to those previously developed in our lab. Given drip mechanics, we              
believe that this technique will deposit PTX in a desirable density that mimics industry standard               
concentration. The combination of PTX density and needle-like excipient microstructure may           
help to better inform the cardiovascular medicine industry to the role of the excipient on PTX                
delivery.  
Another factor that is hypothesized to have a significant effect on the excipient             
microstructure is the hydrophobicity of the Nylon sheet on which the drug solution is dispersed.               
We predict that a more hydrophilic surface will allow the drug solution to be more uniformly                
dispersed across the Nylon sheet even as crystal formation begins. As crystals begin to form a                
phenomena known as “wicking” begins to occur with the remaining drug solution. Surface             
treatment of the Nylon sheet with an ozone-plasma cleaner would decrease hydrophobicity of the              
surface, by cleaving C-C bonds to form polar hydroxyl groups, and lessen the “wicking” effect. 
The last factor we aim to explore is the ratio of PTX chemotherapeutic drug to the urea                 
excipient concentration. Alterations in this ratio will affect where, and at what density, the PTX               
is most available to the endothelial model. Ratios containing a greater concentration of urea will               
most likely generate more coating clusters that contain smaller densities of PTX, while             
increasing the ratio of Urea to PTX will produce larger, less frequent excipient clusters that               
contain a more dense concentration of PTX. By increasing the amount of Urea deposited on the                
surface there will be more urea molecules capable of forming larger clusters of microcrystals.              
Given a constant PTX weight across these ratios, as the size of the urea crystals increase, the                 
concentration of PTX per urea crystal will be diluted. We hypothesize that increasing the urea               
concentration in relation to PTX will produce a more efficacious drug delivery profile as a result                
of the greater drug coated surface area. 
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 In summary, PAD poses a serious health risk to a large number of people and an aging                 
population requires improved endovascular intervention. The paclitaxel drug coated balloon          
provides a fast and simple solution to plaque buildup in the arteries of the extremities and does                 
not require a permanent implantation. Through this design project, we hope to better understand              
the factors that control formation of the crystalline urea microstructure and use this information              
to better design the microstructure to deliver PTX to the arterial wall. 
  
[Goals / Objectives] 
Goal 1. Affect systemic change in loading protocol to determine optimum drug-coating            
technique. 
O.1A​ - Urea/PTX coat at a density of 3.5 µg/mm​2​ ​+​ 0.3 µg/mm​2​. 
O.1B​ - 80% drug coating on nylon surface. 
O.1C​ - Uniform surface depth average of 30 µm. 
O.1D​ - Variability in depth less than ​+​ 6 µm. 
  
Goal 2. ​Improved mechanical testing protocol for observation of adhesive forces and drug             
transfer. 
O.2A - Detection and quantification of adhesive forces ​> 1% of compressive force on an area                
1 cm​2​ of porcine arterial endothelium (PAE). 
O.2B​ - PTX delivery efficacy ≥10% to the porcine arterial tissue. 
  
 
[Methodology] 
Surface Treatment of Nylon-12 Sheets. ​1x1-inch squares were cut out of Nylon-12 sheets and              
washed thoroughly with Dawn dish soap and water. The Nylon-12 sheets were submerged and              
sonicated in 200 proof Ethanol for 5 mins. The Nylon-12 sheets were removed and dried under                
N​2 gas. To decrease hydrophobicity of the sheets, they were treated with a UV-Ozone cleaner               
and the treatment was halted at specified time points to create unique hydrophobicity profiles.              
The surface treatment of the nylon model will play an important role in developing nucleation               
sites for the urea microcrystals. A greater degree of nucleation sites should allow for earlier               
formation of crystals during the coating dehydration period. 
 
Creating Drug-Coated Nylon Sheets for SEM Imaging. ​1x1-inch squares were cut out of             
Nylon-12 sheets. The Nylon-12 sheets were glued to 3D printed blocks with Elmer's Glue.              
Uniform, constant pressure was applied between the test block and Nylon sheet for at least               
24 hours to allow for complete dehydration of EtOH from the samples. The following precursor              
drug-coating solutions were formulated: 12.1 mg PTX and 12.1 mg Urea were dissolved in          
1 mL 200 Proof Ethanol (1:1 PTX:Urea); 12.1 mg PTX and 24.2 mg Urea were dissolved in           
1 mL 200 Ethanol Ethanol (1:1 PTX:Urea). 0.160 mL of the precursor drug-coating solutions           
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 was pipetted onto each glued Nylon sheet. The coating solutions were allowed to dehydrate at               
various temperatures environments: Room temperature (RT, 23°C), 4°C Fridge, and 37°C           
Incubator. The samples were moved to room temperature after the dehydration process had             
completed (12 hours) (​O.1A​). 
  
Preparation and SEM of Drug-Coated Nylon Sheets. ​The Nylon sheets were peeled off the              
testing blocks. A biopsy punch was used to cut out circles from the drug-coated Nylon sheets.                
The samples were attached to aluminum holder stubs with double-sided carbon tape.            
Gold-palladium nanoparticles were sputter-coated on the surface of the drug-coated Nylon-12           
sheet using a sputter coater with sputtering rate set to 1, voltage set to 2.5 kV and current set to                   
20 mA. A thickness of 7.5 angstroms was selected as standard protocol for non-conductive            
samples like our Nylon-12. Scanning electron microscopy (SEM) was used to assess the quality              
of coating, thickness and uniform distribution of thickness and to evaluate the quality of drug               
transfer by comparing used and unused coated Nylon-12 sheets. ​The University of South             
Carolina’s Electron Microscopy Center allowed us to use their Tescan SEM to take SEM images               
(​O.1B​). 
 
Image Processing. ​SEM Images was processed using various protocols in the MountainMaps            
Premium 7.4.8803 software. The bottom banner of each SEM image was cropped out in order to                
not interfere with the automated processing. To accurately assess coating topography and            
uniformity, the SEM images were set to a greyscale, where brighter pixels were higher in               
elevations compared to darker pixels. Achieving uniformity allowed for consistent, reproducible           
drug delivery to the arterial wall through all cross sections of the applied area. Elevations were                
directly quantified by measuring the tallest crystal feature in the profile SEM images and linearly               
correlating these elevations to the brightest pixel in the horizontal SEM images. The particle              
processing protocol was used to differentiate crystal clusters with single nucleation sites. Particle             
sizes <50 µm were deemed as random crystals and were removed from processing. Average             
particle sizes were determined for each SEM image for quantification.(​O.1C). 
  
Uniaxial Mechanical Testing of Drug-Coated Nylon Sheets. ​The BOSE Electroforce©          
Uniaxial Tester was utilized to perform the mechanical testing simulating DCB inflation against             
arterial tissue. Two separate 3D-printed testing blocks were utilized; one glued with a             
drug-coated Nylon-12 sheet and the other with nine biopsy punches of porcine arterial tissue              
acquired from Innovative Research. Porcine arterial tissue is a good model for human arterial              
tissue as it has similar arterial dimensions and elasticity.​17 The bottom of the 3D-printed testing               
blocks were constrained by the bottom and top clamps of the uniaxial tester. Three loading and                
displacement-controlled dwell setting protocols were used; the drug-coated Nylon-12 sheet and           
porcine arterial tissue were held together at a load force of 1, 2, or 3 N for 30, 60, or 120                    
seconds. The loading and unloading rates were 0.1 N/s and 0.008 mm/s, respectively. Uniaxial            
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 testing is representative of what will be happening when the balloon is deployed within the               
human artery as there will only be force in one direction (​O.2A​). After the uniaxial mechanical                
testing, the porcine arterial tissue were removed from the testing blocks. The arterial tissue and               
drug-coated Nylon-12 sheet were snapfreezed by submerging in liquid nitrogen for 10 minutes.            
(​O.2A​) 
  
High Performance Liquid Chromatography (HPLC). ​The tissue and post-transfer,         
drug-coated Nylon-12 sheets were submerged in diethyl ether for 24 hours in order to extract              
PTX. The diethyl ether was evaporated off in a distillation column. The PTX was recrystallized               
in 200 proof ethanol to remove impurities. The crystallized PTX was redissolved in HPLC-grade              
methanol. The HPLC separation of PTX was adapted from Badea I et al.​18 The HPLC column                
was flushed with HPLC-grade methanol for 15 minutes. PTX separation was achieved through             
an automated gradient elution: 0 to 18 min, 40% acetonitrile; 18 to 20 min, 45% acetonitrile; and              
20-35 min, 100% acetonitrile. The injection volume was 10 µL and the mobile phase flow rate             
was set to 1 mL/min. A standard solution of PTX in HPLC-grade methanol was injected into the                
HPLC column and allowed to elute. The eluting time range of PTX was determined. For all                
samples, the eluent was collected at this time range. A serial dilution with known concentrations               
was made of PTX in Methanol and injected. This serial dilution will give us a defined range of                  
PTX concentrations along a logarithmic scale and allow us to accurately interpolate the             
concentration of PTX recovered from the porcine arterial tissue. 20 µL of all eluents were              
pipetted into a 96-well plate. The 96-well plate was placed into a well-plate spectrophotometer              
and scanned at a wavelength of 230 nm (𝜆 ​max of PTX) A absorbance vs concentration calibration               
curve was made from the eluents of the serial dilution. All absorbances were plotted on this                
calibration curve to determine the PTX concentration of each eluent (​O.2B​). 
  
Results  
Based on literature review, the variables of drug-dehydration temperature, excipient to drug            
ratio, surface coatings, and drug coating technique were identified as having the potential for              
affecting excipient crystallinity. Furthermore, altering the excipient crystallinity may have an           
impact on the adhesion mechanics between the coating and arterial tissue. Experiments were             
formulated based on altering these variables and observing the effects on the topography of the               
coating. The macroscopic images of the drug coating are shown in ​Figure​ ​2​.  
 
SEM was performed on the first set of sample coatings (1:1 PTX-Urea dehydrated at              
23°C) to examine the reproducibility and reliability of our methods. The SEM images are shown               
in ​Figure 3​, and demonstrate the needle-like formations previously demonstrated by our            
laboratory. The clusters formed from coating at this temperature and ratio are in good agreement               
with the predicted results, and because of this we moved forward with the variables to be altered.  
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 To assess how deviations in temperature and concentration affect crystal formation and            
the excipient microstructure, SEM was then performed on samples of varying concentration            
ratios (1:2 PTX-Urea dehydrated at 23°C) and temperatures (1:1 PTX-Urea dehydrated at 4°C             
and 37°C). These images are displayed in ​Figure 4. Unlike samples dehydrated at 4°C and 37°C,                
the room temperature sample did not generate urea clusters, but rather appears sheetlike on the               
top surface of the nylon model. It should be noted that this sample is the only 2:1 Urea:PTX                  
concentration in this figure, given that the 1:1 ratio at room temperature can be seen in ​Figure 3​.                  
The samples dehydrated at biological temperature, 37, demonstrate a greater number of, and             
much larger, urea clusters then the sample at 4°C.  
 
To reconstitute a 3D model of the drug coatings from the SEM images, the tallest features                
of each sample are determined and assigned to grayscale values on each SEM image. For this,                
profile and landscape SEM images were taken; these are displayed in ​Figure 5 ​and ​Figure 6​,                
respectively. ​Figure 5 illustrates the coating depth that is achievable when the urea microcrystals              
grow during sample dehydration. The needle-like clusters develop a variable surface topography            
that contains both protruding microcrystals and uncoated, exposed nylon model. ​Figure 6 shows             
the variation in microcrystal formation across the surface of the nylon model, which helps to               
demonstrate the inherent variability of the drug-coated nylon surface. 
  
Figure 7 presents SEM images of pre-treated nylon surfaces with a 1:1 PTX:Urea ratio              
and dehydrated at 23​0​C. Figures 7A and 7C were UV-ozone treated for 20 minutes to decrease                
surface hydrophobicity while figures 7B and 7D were treated for 40 minutes. The 20 minute               
sample shows clear urea microcrystals like those found in samples without UV-ozone            
pretreatment. The sample treated for 40 minutes did not form needle-like clusters and instead              
produced amorphous groupings of drug coating. This figure illustrates that surface           
hydrophobicity plays some role in the ability for the excipient microstructure to form, as well as                
the grouping and shape of the microstructure.  
 
All SEM images were then processed using the MountainMaps software to acquire            
quantitative data for analysis. The image processing for 1:1 PTX-Urea dehydrated at 23°C             
coating is shown in ​Figure 8​. Using the MountainMaps software it is possible to identify and                
remove the nylon surface from SEM images, leaving only quantifiable crystal clusters to be              
assessed. These clusters can then be separated based off of cluster diameter and analyzed to               
determine metrics about the urea’s ability to cluster under varied coating conditions. 
 
Upon completing SEM, samples were compressed against a porcine artery at 8 N             
and 12 N for 30 s and 180 s. Then, PTX was extracted from the samples and eluted through                   
HPLC to determine drug transfer. The mean drug transfer concentrations for 4℃, 23℃, and              
37℃ were 0.077 ug/mL (5.11%), 0.072 ug/mL (4.77%), and 0.06617 ug/mL (4.39%)            
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 respectively. Percentages represent the percentage of total drug on nylon-12 sheet transferred to             
porcine artery. One way ANOVA (Kruskal-Wallis p = 0.12) and two-tailed T-tests showed no              
statistically significant difference between samples dehydrated at the various temperatures          
(​Figure 9​). The mean drug transfer concentrations of samples treated with ozone for 0min,              
20min, and 40 min followed by dehydration at 23℃ were 0.07575 ug/mL (5.02%), 0.4265              
ug/mL (28.28%) and 0.19583 ug/mL (12.99%) (​Figure 10​). There were statistically significant            
differences between samples not treated with ozone, treated for 20 min, and treated for 40 min                
using a one-way ANOVA (Kruskal-Wallis p = 0.00016). Furthermore, two-tailed T-tests confirm            
that there were statistical differences between the non-treated and 20 min treatment (p             
=0.00092), the non-treatment and the 40 min treatment (p = 0.0033), and between the 20 min and                 
40 min treatments (p = 0.031). Statistical analysis was carried out using the R software package                
ggpubr​. 
 
 
Figure 2. Macroscopic images of Drug Coating at various temperatures. 160 mL of 1:1             
(12.1 mg/mL, 12.1 mg/mL) and 1:2 (12.1 mg/mL, 24.2 mg/mL) PTX-Urea were pipetted to          
1x1-inch Nylon-12 sheets glued on 3-D printed test blocks with Elmer’s Glue. The coating              
solutions were dehydrated at 37°C, room temperature, and 4°C for at least 12 hrs. 
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Figure 3.​ ​SEM Images of 1:1 PTX-Urea coated Nylon-12 sheets dehydrated at 23°C. ​The 
magnifications were 50x (A, B), 300x (C, D) , and 1500x (E, F).  
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Figure 4. ​SEM Images of Coated Nylon-12 sheets dehydrated at various room temperature.             
Samples were 1:1 PTX-Urea dehydrated at 4°C (A, D, G) , 1:2 PTX-Urea dehydrated at 23°C                
(B, E, H), and 1:1 PTX-Urea dehydrated at 37°C (C, F, I). The magnifications were 70x (A, B,                  
C) , 420x (D, E, F), and 1500x (G, H, I).  
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Figure 5. Profile SEM Images of Coated Nylon-12 sheet. ​The samples were 1:1 PTX-Urea              
dehydrated at 23°C. The magnifications were (A) 1000x and (B) 753x. 
 
 
Figure 6. Landscape SEM Images of Coated Nylon-12 sheet. ​The samples were 1:1 
PTX-Urea dehydrated at 23°C. The magnification was 1000x. Images were taken of the (A) 
foreground, (B) midground, and (C) background. 
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Figure 7. SEM Images of Surface-Treated, Coated Nylon-12 Sheets. ​The Nylon-12 sheets            
were UV-Ozone treated for (A, C) 20 mins and (B, D) 40 mins. The magnifications were (A, B)                
100x and (C, D) 350x. 
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Figure 8. Image Processing of SEM Image of 1:1 PTX-Urea dehydrated at 23°C sample.              
The image processing software MountainMaps was used to obtain quantitative data from SEM             
images. The background of the SEM image was identified (A) and removed (B). All crystal               
clusters were identified (C) and differentiated (D). Crystal clusters larger than 50 µm (E) were              
separated from those smaller than 50 µm (F). 
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Figure 9. Statistical Analysis of the PTX transfer from drug coating of varying dehydration              
temperatures to porcine artery. ​PTX transfer was quantified with HPLC. The dehydration            
temperatures were 4°C, 23°C, and 37°C. Two-tailed T-Test p-values are displayed above the             
brackets.  
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Figure 10. Statistical Analysis of the PTX transfer from drug coating of varying durations              
of UV-Ozone treatment to porcine artery. ​PTX transfer was quantified with HPLC. The             
UV-Ozone treatment durations were 0, 20, and 40 mins. Two-tailed T-Test p-values are             
displayed above the brackets.  
 
Conclusions 
We have generated SEM images of our samples at various dehydration temperatures and             
various ratios of Urea:PTX. It appears that as the temperature of dehydration increases, the              
crystalline microstructure increases in size and uniformity. By increasing the temperature, the            
ethanol vehicle evaporates quicker and thereby causes rapid crystallization of the urea from             
many nucleation sites. We cannot generate quantitative data at the moment as the TESCAN SEM               
was not calibrated correctly and since we have not achieved uniform surface coatings across              
repetitive samples. However, once the samples are regenerated and the SEM is recalibrated, we              
have acquired the skills to quickly scan and process our images using the Mountain Maps               
software. 
 
The 2:1 Urea-PTX 23°C coating surface appears to show no or limited crystal clusters;              
the surface profile appears to be smoother compared to that of the 1:1 Urea-PTX 23°C coating.                
We theorize that this is due to the excessively high concentration of urea, where nucleation sites                
of urea crystals did not have enough space to distribute across the Nylon sheet. Thus, the urea                 
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 molecules uniformly distribute across the Nylon sheet as the coating solution is dehydrated and              
begins to form a crystalline surface. Further experiments with various concentration ratios must             
be performed to confirm this. 
 
One of the biggest limitations of our project is the fact that the TESCAN SEM machine                
was not calibrated correctly. This affects our project because we can no longer generate              
quantitative results from our images that we have already received. What we have done instead is                
create qualitative and descriptive characteristics and pair those results with the protocol we used              
to coat the samples. Moving forward, our lab will still continue with uniaxial mechanical testing               
and HPLC testing of the samples that we have created and imaged. New samples will be created                 
when the SEM machine is calibrated. 
 
Another limitation to this project has been the inability to develop uniform surface             
coatings across repetitive treatments. We believe this is due, in large part, to the varying               
humidities present at 4°C, 23°C, and 37°C. As seen in ​Figure 9​, temperature plays no role in                 
drug delivery. Therefore, moving forward our lab will only dehydrate samples at 23°C in a               
dessicator to remove interference of ​humidity and allow for ease of sample creation. Urea is               
hygroscopic and by placing our samples in a desiccator, we can eliminate this potential issue. By                
decreasing this variability the qualitative results obtained from the un-calibrated SEM will have             
greater weight. 
 
[Future Plans] 
HPLC results showed that the Ozone surface treatment was the most effective at             
increasing PTX delivery into the artery. However, this was not optimized as an increase from 20                
min to 40 min actually decreases drug delivery. Our lab will proceed to optimize this treatment                
by performing several ozone treatment times between 0 and 40 minutes and determining optimal              
drug transfer using HPLC and statistical analysis.  
 
Further investigations into the Urea and PTX coated DCB’s will need to recreate the              
arterial flow conditions present in peripheral arteries. Our study did not explore the effect of flow                
on PTX delivery given constraints on testing equipment and the scope of this project. Clinical               
studies on the delivery of PTX with DCBs have found that arterial flow conditions can hydrate                
the urea surface coating and subsequently remove PTX available to the arterial wall. Due to this                
undesirable drug elimination, industry leaders have been unable to achieve PTX delivery in             
excess of 7% PTX mass. Flow conditions will likely reduce the amount of PTX that can be                 
delivered by forcing the drug off of the balloon and nonspecifically into the vessel prior to DCB                 
inflation and plaque compression.  
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 Beyond flow conditions, the microstructure of the urea may damage the endothelial            
lining in the peripheral arteries. More pronounced needle-like structures may lead to greater             
disruption of the glycocalyx layer which will have significant impact on the arteries ability to               
mechanoregulate. This disruption of the glycocalyx layer will adversely impact the objective of             
reestablishing lumen patency, which is a concern for patient outcome. Future studies should aim              
to qualify the glycocalyx disruption as well as explore the negative impacts this disruption will               
have on arterial regulation. 
 
Finally, while the arterial lumen has been shown relatively uniform throughout the            
human body, the composition of the arterial media and adventitia ranges significantly between             
major and minor arteries found within the periphery. This report focuses on the clinical              
applications of DCBs as it pertains to reestablishing the lumen patency of peripheral arteries and               
does not explore the role that varying arterial composition has on endovascular interventions. For              
a more comprehensive assessment of the role DCBs play on the function of the vasculature, the                
impact of unique media and adventitia properties should be considered. This consideration is             
beyond the scope of this report.  
 
[Budget] 
The University of South Carolina Biomedical Engineering Program will provide $1000 towards            
the budget for this project. Additional funds will be provided by project sponsor. The material               
budget has been provided in ​Table 1, the operating budget has been provided in ​Table 2​. The                 
highlighted portions emphasize what parts of the budget are critical for completing our goals.              
The concentration of Paclitaxel and Urea will be change in order to investigate the optimum               
crystalline microstructure.. The Porcine Blood Vessel is critical to observe the adhesion forces             
from the crystalline microstructure. The FESEM, HPLC, and BOSE Electroforce© Uniaxial           
Tester are the processes and devices we will need to confirm that we have met each objective for                  
each goal. 
 
Table 1: ​Materials Budget. The price of materials used for experimentation and assessment             
including supplier and function. Materials marked with an asterisk (*) will be provided by the               
project sponsor and are not included in the total cost calculation. 
Material Price Distributor Use 
Paclitaxel (100​ ​mg) $116.41* Alfa Aesar Lipophilic Chemostatic Drug 
Urea ( 6 x 25​ ​mL ) $45.50 Millipore Sigma Excipient 
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 Polyamide- Nylon 12 
(thickness 0.5 mm, 
size 150 x 150 mm) 
$193.91 Millipore Sigma Balloon Model 
Ethanol (1 L) x 3 $71.00* x 3 Millipore Sigma Solvent for Paclitaxel and Urea, 
cleaning agent 
Diethyl Ether ( 1 L) $92.50 Millipore Sigma Extract Paclitaxel from 
Endothelium 
HPLC-Grade 
Methanol 
$70.50 Millipore Sigma Paclitaxel Solvent for HPLC 
Polystyrene Mounting 
Block 
$200.00* TA Instruments Constrain Samples and Tissue 
for Mechanical Testing 
Porcine Blood Vessel $100.00* Innovative 
Research 
Model Drug Transfer, Simulate 
Contact Mechanics 
Total Material 
Budget 
$401.91 + $529.41* *Materials Provided by 
Sponsor 
  
Table 2: Lab Equipment Budget. Operating expenses for equipment not directly available to             
the experimenters including location and purpose. 
Operation Cost Facility Use 
Scanning Electron Microscopy 
(Tescan Vega3 SBU) 
$50.00 / 
Hour 
USC Electron 
Microscopy 
Center 
Image Surface of Nylon 
Model 
Field Emission Scanning 
Electron Microscopy (Zeiss 
Ultra Plus) 
$80.00 / 
Hour 
USC Electron 
Microscopy 
Center 
Characterize 
Microstructural 
Topography 
High Performance Liquid 
Chromatography (HPLC) 
$20.00 / 
Sample 
USC Mass 
Spectrometry 
Lab 
Quantify Drug Transfer 
and Loading Density 
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 MountainMaps Temporary license available 
to Dara Azar within the 
Shazly lab 
Quantify Surface 
Imaging 
BOSE Electroforce© Uniaxial 
Tester 
Available Through Dr. Tarek 
Shazly’s Laboratory 
Perform Uniaxial 
Testing 
Operational Budget $1,000 – ​($401.91)​ = 
$598.09 
Red – Indicates Material 
Cost of Goods 
  
[Timeline] 
The timeline is composed of tasks to be completed by the end of May 2019. At the conclusion of                   
Fall 2018, the design team had done sufficient literature research to develop experimental             
protocols and had subsequently received the necessary laboratory trainings. This allowed the            
team to begin coating nylon samples and characterizing some of these samples before breaking              
for the winter recess. After regrouping at the beginning of Spring 2019, the team began               
collecting and quantifying the SEM data. This informed the mechanical testing that was             
performed, as well as the drug transfer quantified using HPLC techniques. Having completed             
these experiments, the team was able to draw relationships between coating protocol and rate of               
drug transfer. These relationships and conclusions are outlined within this report.The progress of             
each task needed to complete our goals in the respective amount of time is shown in ​Figure 11​.  
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Figure 11. Timeline with important dates and progress of each task. ​This Gantt chart shows               
the tasks that must be completed in order to finish our two goals on time. The figure has                  
important dates labeled at the top including assignment due dates and goal completion dates. The               
task is labeled to the left of each progress bar and the start dates and completion dates are on the                    
right. The percentage of completion is in the middle of the progress bar. 
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